Estimated market cap $129.33MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Dec 31, 2025, last close Nov 13, 2026.93.72M ADSs, shares as of Dec 31, 2025CIK 1598599The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
—
No open-market trades
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Innate Pharma S.A.'s latest quarterly report, compared with the one before.
We have not read a recent 10-Q for this company yet.
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Innate Pharma S.A. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
7
0 added · 2 trimmed
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No recent insider purchases or sales for this company.
13F holders
90,631 shares
7 funds report IPHA. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Q3 2026. 3 new, 0 added to, 2 trimmed, 6 exited since Q2 2026.
Download CSVEvery fund that holds IPHA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Innate Pharma S.A. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q4 2019
12
—
7.71M
$49.7M
Q1 2020
10
-2
7.34M
$49.0M
Q2 2020
7
-3
2.87M
$20.3M
Q3 2020
6
-1
1.68M
$6.7M
Q4 2020
4
-2
1.40M
$5.7M
Q1 2021
7
+3
176,678
$762.6K
Q2 2021
5
-2
89,540
$296.0K
Q3 2021
18
+13
943,114
$5.8M
Q4 2021
16
-2
1.39M
$6.5M
Q1 2022
13
-3
952,297
$3.2M
Q2 2022
13
0
954,367
$2.6M
Q3 2022
12
-1
944,461
$1.9M
Q4 2022
11
-1
399,882
$1.5M
Q1 2023
9
-2
397,077
$1.1M
Q2 2023
9
0
235,270
$735.6K
Q3 2023
8
-1
318,407
$805.6K
Q4 2023
8
0
175,266
$490.7K
Q1 2024
9
+1
342,166
$985.4K
Q2 2024
8
-1
241,754
$469.0K
Q3 2024
8
0
238,049
$545.1K
Q4 2024
9
+1
137,970
$254.8K
Q1 2025
10
+1
158,189
$281.6K
Q2 2025
9
-1
99,838
$178.7K
Q3 2025
9
0
81,617
$157.9K
Q4 2025
11
+2
276,273
$483.5K
Q1 2026
9
-2
183,951
$235.5K
Q2 2026
10
+1
192,418
$354.0K
Q3 2026
7
-3
90,631
$147.7K
Each point is a quarter-end, from Q4 2019 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (45781K204). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2019) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.